Alder BioPharmaceuticals (ALDR) Upgraded by ValuEngine to Sell

Cornelia Mascio
Mag 17, 2018

ALDR has been the subject of a number of research analyst reports. BidaskClub downgraded Alder BioPharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, March 20th.

Wall Street brokerages expect Alder BioPharmaceuticals (NASDAQ:ALDR) to post earnings per share (EPS) of ($1.26) for the current fiscal quarter, according to Zacks. With 882,400 shares average volume, it will take short sellers 13 days to cover their ALDR's short positions. Leerink Swann reiterated an "outperform" rating on shares of Alder BioPharmaceuticals in a report on Sunday, March 4th. The stock presently has an average rating of "Buy" and an average target price of $26.77. Its up 2.66% from 11.01 million shares, reported previously.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland.The company has $1.03 billion market cap.

Alder BioPharmaceuticals (NASDAQ:ALDR) released its quarterly earnings data on Tuesday, May 8th. ValuEngine lowered Alder BioPharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Friday, February 2nd. The short interest to Alder Biopharmaceuticals Inc's float is 20.05%. PA increased its holdings in shares of Alder BioPharmaceuticals by 9.6% during the 4th quarter. The firm has $26.0 highest and $17 lowest target. Alder BioPharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. Foresite Capital Management III LLC increased its holdings in shares of Alder BioPharmaceuticals by 3.3% during the 1st quarter. Brown Advisory Inc. now owns 862,585 shares of the biopharmaceutical company's stock valued at $9,877,000 after purchasing an additional 289,120 shares during the period. Emerald Advisers Inc. PA now owns 1,730,028 shares of the biopharmaceutical company's stock worth $19,809,000 after acquiring an additional 151,551 shares during the period. American International Group Inc. now owns 42,060 shares of the biopharmaceutical company's stock worth $515,000 after acquiring an additional 12,784 shares during the period. Palo Alto Investors LLC increased its holdings in shares of Alder BioPharmaceuticals by 2,757.5% during the 4th quarter. AXA now owns 1,087,209 shares of the biopharmaceutical company's stock worth $12,448,000 after acquiring an additional 95,126 shares during the period. Hedge funds and other institutional investors own 99.10% of the company's stock.

WARNING: This piece of content was first posted by registrarjournal.com and is owned by of registrarjournal.com.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE